Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2019, Article ID 8323592, 12 pages
https://doi.org/10.1155/2019/8323592
Review Article

Targeting Leukemia Stem Cell-Niche Dynamics: A New Challenge in AML Treatment

University of Pavia, Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Correspondence should be addressed to Oscar Borsani; ti.aivapidatisrevinu@10inasrob.racso

Received 2 June 2019; Accepted 18 July 2019; Published 7 August 2019

Guest Editor: Annalisa Lonetti

Copyright © 2019 Paolo Bernasconi and Oscar Borsani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Bose, P. Vachhani, and J. E. Cortes, “Treatment of relapsed/refractory acute myeloid leukemia,” Current Treatment Options in Oncology, vol. 18, no. 3, p. 17, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. A. A. Lane, S. L. Mcafee, J. Kennedy et al., “High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma,” Leukemia & Lymphoma, vol. 52, no. 7, pp. 1363–1366, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Schepers, E. M. Pietras, D. Reynaud et al., “Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche,” Cell Stem Cell, vol. 13, no. 3, pp. 285–299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. D. S. Krause, K. Fulzele, A. Catic et al., “Differential regulation of myeloid leukemias by the bone marrow microenvironment,” Nature Medicine, vol. 19, no. 11, pp. 1513–1517, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Medyouf, “The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications,” Blood, vol. 129, no. 12, pp. 1617–1626, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Bernasconi, M. Farina, M. Boni, I. Dambruoso, and C. Calvello, “Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: a worthy endeavor?” American Journal of Hematology, vol. 91, no. 5, pp. 507–517, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. D. A. Sipkins, X. Wei, J. W. Wu et al., “In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment,” Nature, vol. 435, no. 7044, pp. 969–973, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Ishikawa, S. Yoshida, Y. Saito et al., “Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region,” Nature Biotechnology, vol. 25, no. 11, pp. 1315–1321, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Ninomiya, A. Abe, A. Katsumi et al., “Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice,” Leukemia, vol. 21, no. 1, pp. 136–142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Colmone, M. Amorim, A. L. Pontier, S. Wang, E. Jablonski, and D. A. Sipkins, “Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells,” Science, vol. 322, no. 5909, pp. 1861–1865, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Hanoun, D. Zhang, T. Mizoguchi et al., “Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche,” Cell Stem Cell, vol. 15, no. 3, pp. 365–375, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. B. J. Frisch, J. M. Ashton, L. Xing, M. W. Becker, C. T. Jordan, and L. M. Calvi, “Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia,” Blood, vol. 119, no. 2, pp. 540–550, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Duarte, E. D. Hawkins, and C. Lo Celso, “The interplay of leukemia cells and the bone marrow microenvironment,” Blood, vol. 131, no. 14, pp. 1507–1511, 2018. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Abarrategi, K. Foster, A. Hamilton et al., “Versatile humanized niche model enables study of normal and malignant human hematopoiesis,” Journal of Clinical Investigation, vol. 127, no. 2, pp. 543–548, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Passaro, A. Di Tullio, A. Abarrategi et al., “Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia,” Cancer Cell, vol. 32, no. 3, pp. 324–341.e6, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Czechowicz, D. Kraft, I. L. Weissman, and D. Bhattacharya, “Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches,” Science, vol. 318, no. 5854, pp. 1296–1299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Miraki-Moud, F. Anjos-Afonso, K. A. Hodby et al., “Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation,” Proceedings of the National Academy of Sciences, vol. 110, no. 33, pp. 13576–13581, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Sackstein, “A revision of Billingham’s tenets: the central role of lymphocyte migration in acute graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 12, no. 1, pp. 2–8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Glait-Santar, R. Desmond, X. Feng et al., “Functional niche competition between normal hematopoietic stem and progenitor cells and myeloid leukemia cells,” Stem Cells, vol. 33, no. 12, pp. 3635–3642, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. A. L. Boyd and M. Bhatia, “Playing musical chairs with bone marrow transplantation to eliminate leukemia stem cells,” Molecular & Cellular Oncology, vol. 2, no. 3, Article ID e988480, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. O. Ringdén, A. J. Barrett, M.-J. Zhang et al., “Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses,” British Journal of Haematology, vol. 121, no. 6, pp. 874–885, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Tavor, I. Petit, S. Porozov et al., “CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice,” Cancer Research, vol. 64, no. 8, pp. 2817–2824, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Fiegl, I. Samudio, K. Clise-Dwyer, J. K. Burks, Z. Mnjoyan, and M. Andreeff, “CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure,” Blood, vol. 113, no. 7, pp. 1504–1512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. K. N. Kremer, K. L. Peterson, P. A. Schneider et al., “CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak,” Journal of Biological Chemistry, vol. 288, no. 32, pp. 22899–22914, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. E. J. Rombouts, B. Pavic, B. Löwenberg, and R. E. Ploemacher, “Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia,” Blood, vol. 104, no. 2, pp. 550–557, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Y. Ahn, K. Seo, O. K. Weinberg, and D. A. Arber, “The prognostic value of CXCR4 in acute myeloid leukemia,” Applied Immunohistochemistry & Molecular Morphology, vol. 21, no. 1, pp. 79–84, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Konoplev, G. Z. Rassidakis, E. Estey et al., “Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype,” Cancer, vol. 109, no. 6, pp. 1152–1156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Nervi, P. Ramirez, M. P. Rettig et al., “Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100,” Blood, vol. 113, no. 24, pp. 6206–6214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. I. G. Winkler, V. Barbier, B. Nowlan et al., “Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance,” Nature Medicine, vol. 18, no. 11, pp. 1651–1657, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. Z. Zeng, Y. X. Shi, I. J. Samudio et al., “Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML,” Blood, vol. 113, no. 24, pp. 6215–6224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. Z. Zeng, Y. X. Shi, T. Tsao et al., “Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment,” Blood, vol. 120, no. 13, pp. 2679–2689, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. G. L. Uy, M. P. Rettig, I. H. Motabi et al., “A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia,” Blood, vol. 119, no. 17, pp. 3917–3924, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. F. V. Michelis, D. W. Hedley, S. Malhotra et al., “Mobilization of leukemic cells using plerixafor as part of a myeloablative preparative regimen for patients with acute myelogenous leukemia undergoing allografting: assessment of safety and tolerability,” Biology of Blood and Marrow Transplantation, vol. 25, no. 6, pp. 1158–1163, 2019. View at Publisher · View at Google Scholar · View at Scopus
  34. C. R. Cogle, D. C. Goldman, G. J. Madlambayan et al., “Functional integration of acute myeloid leukemia into the vascular niche,” Leukemia, vol. 28, no. 10, pp. 1978–1987, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Bonig, A. Wundes, K.-H. Chang, S. Lucas, and T. Papayannopoulou, “Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab,” Blood, vol. 111, no. 7, pp. 3439–3441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Bloomgren, S. Richman, C. Hotermans et al., “Risk of natalizumab-associated progressive multifocal leukoencephalopathy,” New England Journal of Medicine, vol. 366, no. 20, pp. 1870–1880, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Chien, X. Zhao, M. Brown et al., “A novel small molecule E-selectin inhibitor GMI-1271 blocks Adhesion of AML Blasts to E-Selectin and mobilizes blood Cells in nodscid IL2Rgc–/– mice Engrafted with human AML,” Blood, vol. 120, no. 21, p. 4092, 2012. View at Google Scholar
  38. J. Bajaj, T. Konuma, N. K. Lytle et al., “CD98-Mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia,” Cancer Cell, vol. 30, no. 5, pp. 792–805, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Spiegel, S. Shivtiel, A. Kalinkovich et al., “Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34+ cells through Wnt signaling,” Nature Immunology, vol. 8, no. 10, pp. 1123–1131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Heissig, K. Hattori, S. Dias et al., “Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand,” Cell, vol. 109, no. 5, pp. 625–637, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Benito, Y. Shi, B. Szymanska et al., “Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104,” PLoS One, vol. 6, no. 8, Article ID e23108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. B. T. Mortensen, P. Ø. Jensen, N. Helledie et al., “Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats,” British Journal of Haematology, vol. 102, no. 2, pp. 458–464, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. P. O. Jensen, B. T. Mortensen, R. J. Hodgkiss et al., “Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats,” Cell Proliferation, vol. 33, no. 6, pp. 381–395, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Benito, M. S. Ramirez, N. Z. Millward et al., “Hypoxia-activated prodrug TH-302 targets hypoxic bone marrow niches in preclinical leukemia models,” Clinical Cancer Research, vol. 22, no. 7, pp. 1687–1698, 2016. View at Publisher · View at Google Scholar · View at Scopus
  45. S. K. Ramasamy, A. P. Kusumbe, M. Schiller et al., “Blood flow controls bone vascular function and osteogenesis,” Nature Communications, vol. 7, no. 1, Article ID 13601, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Wang, Y. Liu, S. N. Malek, P. Zheng, and Y. Liu, “Targeting HIF1α eliminates cancer stem cells in hematological malignancies,” Cell Stem Cell, vol. 8, no. 4, pp. 399–411, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. X. N. Gao, F. Yan, J. Lin et al., “AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation,” Leukemia, vol. 29, no. 8, pp. 1730–1740, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Rouault-Pierre, L. Lopez-Onieva, K. Foster et al., “HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress,” Cell Stem Cell, vol. 13, no. 5, pp. 549–563, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. E. D. Lagadinou, A. Sach, K. Callahan et al., “BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells,” Cell Stem Cell, vol. 12, no. 3, pp. 329–341, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Konopleva, R. Contractor, T. Tsao et al., “Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia,” Cancer Cell, vol. 10, no. 5, pp. 375–388, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Pan, L. J. Hogdal, J. M. Benito et al., “Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia,” Cancer Discovery, vol. 4, no. 3, pp. 362–375, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Konopleva, D. A. Pollyea, J. Potluri et al., “Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia,” Cancer Discovery, vol. 6, no. 10, pp. 1106–1117, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Chyla, N. Daver, K. Doyle et al., “Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia,” American Journal of Hematology, vol. 93, no. 8, pp. E202–E205, 2018. View at Publisher · View at Google Scholar · View at Scopus
  54. T. C. Teh, N.-Y. Nguyen, D. M. Moujalled et al., “Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1,” Leukemia, vol. 32, no. 2, pp. 303–312, 2018. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Rahmani, M. M. Aust, E. Attkisson, D. C. Williams, A. Ferreira-Gonzalez, and S. Grant, “Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism,” Cancer Research, vol. 73, no. 4, pp. 1340–1351, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. J. M. Bogenberger, S. M. Kornblau, W. E. Pierceall et al., “BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies,” Leukemia, vol. 28, no. 8, pp. 1657–1665, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. C. D. DiNardo, K. W. Pratz, A. Letai et al., “Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study,” Lancet Oncology, vol. 19, no. 2, pp. 216–228, 2018. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Dombret, J. F. Seymour, A. Butrym et al., “International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts,” Blood, vol. 126, no. 3, pp. 291–299, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. W. Zhang, V. R. Ruvolo, C. Gao et al., “Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells,” Molecular Cancer Therapeutics, vol. 13, no. 7, pp. 1848–1859, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. A. H. Wei and I. S. Tiong, “Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML,” Blood, vol. 130, no. 23, pp. 2469–2474, 2017. View at Publisher · View at Google Scholar · View at Scopus
  61. N. G. Daver, D. A. Pollyea, J. S. Garcia et al., “Safety, efficacy, pharmacokinetic (PK) and biomarker analyses of BCL2 inhibitor venetoclax (ven) plus MDM2 inhibitor idasanutlin (idasa) in patients (pts) with relapsed or refractory (R/R) AML: a phase Ib, non-randomized, open-label study,” Blood, vol. 132, no. 1, p. 767, 2018. View at Publisher · View at Google Scholar
  62. R. Pan, V. Ruvolo, H. Mu et al., “Synthetic lethality of combined bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy,” Cancer Cell, vol. 32, no. 6, pp. 748–760.e6, 2017. View at Publisher · View at Google Scholar · View at Scopus
  63. N. Jacque, A. M. Ronchetti, C. Larrue et al., “Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition,” Blood, vol. 126, no. 11, pp. 1346–1356, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Portwood, D. Lal, Y.-C. Hsu et al., “Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models,” Clinical Cancer Research, vol. 19, no. 23, pp. 6506–6519, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Konopleva, D. Handisides, M. Richie et al., “A phase 1 study of Th-302, an investigational hypoxia-targeted drug, in patients with advanced leukemias,” in Proceedings of the 55th ASH Annual Meeting and Exposition, New Orleans, LA, USA, December 2013.
  66. A. Kalinkovich, S. Tavor, A. Avigdor et al., “Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells,” Cancer Research, vol. 66, no. 22, pp. 11013–11020, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Huan, N. I. Hornick, M. J. Shurtleff et al., “RNA trafficking by acute myelogenous leukemia exosomes,” Cancer Research, vol. 73, no. 2, pp. 918–929, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. C. S. Hong, L. Muller, T. L. Whiteside, M. Boyiadzis et al., “Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia,” Frontiers in Immunology, vol. 5, p. 160, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. B. Kumar and C. C. Chen, “Acute myeloid leukemia remodels endosteal vascular niche into a leukemic niche,” Stem Cell Investigation, vol. 5, p. 34, 2018. View at Publisher · View at Google Scholar
  70. R. Moschoi, V. Imbert, M. Nebout et al., “Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy,” Blood, vol. 128, no. 2, pp. 253–264, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Marlein, L. Zaitseva, R. E. Piddock et al., “Bone marrow mesenchymal stromal cells transfer their mitochondria to acute myeloid leukaemia blasts to support their proliferation and survival,” Blood, vol. 128, no. 22, p. 772, 2016. View at Google Scholar
  72. K. Golan, A. Wellendorf, Y. Takihara et al., “Mitochondria Transfer from hematopoietic Stem and progenitor Cells to pdgfrα+/sca-1/CD48dim BM stromal cells via CX43 gap Junctions and AMPK signaling inversely regulate ROS Generation in both cell populations,” Blood, vol. 128, no. 22, p. 5, 2016. View at Google Scholar
  73. E. M. Kuntz, P. Baquero, T. L. Holyoake, E. Gottlieb, G. V. Helgason et al., “Therapy resistant CML stem cells are dependent on mitochondrial oxidative metabolism for their survival,” Blood, vol. 128, no. 22, p. 932, 2016. View at Google Scholar
  74. K. A. Hartwell, P. G. Miller, S. Mukherjee et al., “Niche-based screening identifies small-molecule inhibitors of leukemia stem cells,” Nature Chemical Biology, vol. 9, no. 12, pp. 840–848, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. M. R. Ricciardi, S. Mirabilii, M. Allegretti et al., “Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias,” Blood, vol. 126, no. 16, pp. 1925–1929, 2015. View at Publisher · View at Google Scholar · View at Scopus
  76. L. S. Pike, A. L. Smift, N. J. Croteau, D. A. Ferrick, and M. Wu, “Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells,” Biochimica et Biophysica Acta, vol. 1807, no. 6, pp. 726–734, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. G. Perea, A. Domingo, N. Villamor et al., “Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients,” Leukemia Research, vol. 29, no. 10, pp. 1109–1116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Ye, B. Adane, N. Khan et al., “Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche,” Cell Stem Cell, vol. 19, no. 1, pp. 23–37, 2016. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Carracedo, L. C. Cantley, and P. P. Pandolfi, “Cancer metabolism: fatty acid oxidation in the limelight,” Nature Reviews Cancer, vol. 13, no. 4, pp. 227–232, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. I. Samudio, R. Harmancey, M. Fiegl et al., “Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction,” Journal of Clinical Investigation, vol. 120, no. 1, pp. 142–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Padró, S. Ruiz, R. Bieker et al., “Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia,” Blood, vol. 95, no. 8, pp. 2637–2644, 2000. View at Google Scholar
  82. C. Suri, J. McClain, G. Thurston et al., “Increased vascularization in mice overexpressing angiopoietin-1,” Science, vol. 282, no. 5388, pp. 468–471, 1998. View at Publisher · View at Google Scholar · View at Scopus
  83. F. Ayala, R. Dewar, M. Kieran, and R. Kalluri, “Contribution of bone microenvironment to leukemogenesis and leukemia progression,” Leukemia, vol. 23, no. 12, pp. 2233–2241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. W. Fiedler, U. Graeven, S. Ergün et al., “Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia,” Blood, vol. 89, no. 6, pp. 1870–1875, 1997. View at Google Scholar
  85. S. Dias, K. Hattori, Z. Zhu et al., “Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration,” Journal of Clinical Investigation, vol. 106, no. 4, pp. 511–521, 2000. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Aguayo, E. Estey, H. Kantarjian et al., “Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia,” Blood, vol. 94, no. 11, pp. 3717–3721, 1999. View at Google Scholar
  87. P. Bernasconi and O. Borsani, “Endosteal vessel integrity: a new therapeutic goal in acute myeloid leukemia?” Stem Cell Investigation, vol. 5, p. 36, 2018. View at Publisher · View at Google Scholar
  88. T. Itkin, S. Gur-Cohen, J. A. Spencer et al., “Distinct bone marrow blood vessels differentially regulate haematopoiesis,” Nature, vol. 532, no. 7599, pp. 323–328, 2016. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Kerkau, R. Schmitt-Landgraf, A. Schimpl, E. Wecker et al., “Downregulation of HLA class I antigens in HIV-1-infected cells,” AIDS Research and Human Retroviruses, vol. 5, no. 6, pp. 613–620, 1989. View at Publisher · View at Google Scholar · View at Scopus
  90. B. Seliger, U. Ritz, and S. Ferrone, “Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation,” International Journal of Cancer, vol. 118, no. 1, pp. 129–138, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. W. J. Norde, W. Hobo, R. van der Voort, and H. Dolstra, “Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention,” Blood, vol. 120, no. 4, pp. 728–736, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Bashey, B. Medina, S. Corringham et al., “CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation,” Blood, vol. 113, no. 7, pp. 1581–1588, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Zhou, A. Bashey, R. Zhong et al., “CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells,” Biology of Blood and Marrow Transplantation, vol. 17, no. 5, pp. 682–692, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. M. S. Davids, H. T. Kim, P. Bachireddy et al., “Ipilimumab for patients with relapse after allogeneic transplantation,” New England Journal of Medicine, vol. 375, no. 2, pp. 143–153, 2016. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Prestipino, A. J. Emhardt, K. Aumann et al., “Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms,” Science Translational Medicine, vol. 10, no. 429, 2018. View at Publisher · View at Google Scholar · View at Scopus
  96. M. O. Holmström, M. D. Hjortsø, S. M. Ahmad et al., “The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms,” Leukemia, vol. 31, no. 2, pp. 495–498, 2017. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Jaiswal, C. H. M. Jamieson, W. W. Pang et al., “CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis,” Cell, vol. 138, no. 2, pp. 271–285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. S. C. Casey, L. Tong, Y. Li et al., “MYC regulates the antitumor immune response through CD47 and PD-L1,” Science, vol. 352, no. 6282, pp. 227–231, 2016. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Herbaux, J. Gauthier, P. Brice et al., “Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma,” Blood, vol. 129, no. 18, pp. 2471–2478, 2017. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Tarafdar, L. E. M. Hopcroft, P. Gallipoli et al., “CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression,” Blood, vol. 129, no. 2, pp. 199–208, 2017. View at Publisher · View at Google Scholar · View at Scopus
  101. K. Naka, T. Hoshii, T. Muraguchi et al., “TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia,” Nature, vol. 463, no. 7281, pp. 676–680, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. J. Lee, Y. Han, H. T. Lu et al., “TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression,” The Journal of Immunology, vol. 158, no. 5, pp. 2065–2075, 1997. View at Google Scholar
  103. G. M. O’Keefe, V. T. Nguyen, and E. N. Benveniste, “Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-beta, IL-4, IL-13 and IL-10,” European Journal of Immunology, vol. 29, no. 4, pp. 1275–1285, 1999. View at Publisher · View at Google Scholar
  104. H. H. Park, M. Kim, B. H. Lee et al., “Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia,” Annals of Clinical and Laboratory Science, vol. 36, no. 1, pp. 7–15, 2006. View at Google Scholar
  105. D. J. DiLillo, J. B. Weinberg, A. Yoshizaki et al., “Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function,” Leukemia, vol. 27, no. 1, pp. 170–182, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. T. Cloppenborg, M. Stanulla, M. Zimmermann, M. Schrappe, K. Welte, and C. Klein, “Immunosurveillance of childhood ALL: polymorphic interferon-gamma alleles are associated with age at diagnosis and clinical risk groups,” Leukemia, vol. 19, no. 1, pp. 44–48, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. S. L. Colpitts, S. W. Stonier, T. A. Stoklasek et al., “Transcriptional regulation of IL-15 expression during hematopoiesis,” Journal of Immunology, vol. 191, no. 6, pp. 3017–3024, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. G. Chen, D. Wu, Y. Wang et al., “Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation,” European Journal of Haematology, vol. 81, no. 3, pp. 226–235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. R. Romee, S. Cooley, M. M. Berrien-Elliott et al., “First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation,” Blood, vol. 131, no. 23, pp. 2515–2527, 2018. View at Publisher · View at Google Scholar · View at Scopus
  110. N. Cieri, B. Camisa, F. Cocchiarella et al., “IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors,” Blood, vol. 121, no. 4, pp. 573–584, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. N. R. Mathew, F. Baumgartner, L. Braun et al., “Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells,” Nature Medicine, vol. 24, no. 3, pp. 282–291, 2018. View at Publisher · View at Google Scholar · View at Scopus
  112. M. D. Buck, D. O’Sullivan, R. I. K. Geltink et al., “Mitochondrial dynamics controls T cell fate through metabolic programming,” Cell, vol. 166, no. 1, pp. 63–76, 2016. View at Publisher · View at Google Scholar · View at Scopus
  113. G. J. van der Windt, B. Everts, C. H. Chang et al., “Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development,” Immunity, vol. 36, no. 1, pp. 68–78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. D. H. Munn, M. D. Sharma, B. Baban et al., “GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase,” Immunity, vol. 22, no. 5, pp. 633–642, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. V. Folgiero, B. M. Goffredo, P. Filippini et al., “Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia,” Oncotarget, vol. 5, no. 8, pp. 2052–2064, 2014. View at Publisher · View at Google Scholar · View at Scopus
  116. J. K. Orleans-Lindsay, L. D. Barber, H. G. Prentice, and M. W. Lowdell, “Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function-implications for the adoptive immunotherapy of leukaemia,” Clinical & Experimental Immunology, vol. 126, no. 3, pp. 403–411, 2001. View at Publisher · View at Google Scholar · View at Scopus
  117. A. G. Buggins, D. Milojkovic, M. J. Arno et al., “Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways,” Journal of Immunology, vol. 167, no. 10, pp. 6021–6030, 2001. View at Publisher · View at Google Scholar
  118. H. Tsukamoto, P. Chernogorova, K. Ayata et al., “Deficiency of CD73/ecto-5-nucleotidase in mice enhances acute graft-versus-host disease,” Blood, vol. 119, no. 19, pp. 4554–4564, 2012. View at Publisher · View at Google Scholar · View at Scopus
  119. N. Dulphy, G. Henry, P. Hemon et al., “Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis,” British Journal of Haematology, vol. 165, no. 5, pp. 722–725, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. D. Passaro and D. Bonnet, “How to say NO to vascular disruption and stem cell mobilization,” Expert Opinion on Therapeutic Targets, vol. 22, no. 7, pp. 563–565, 2018. View at Publisher · View at Google Scholar · View at Scopus
  121. X. Hao, H. Gu, C. Chen et al., “Metabolic imaging reveals a unique preference of symmetric cell division and homing of leukemia-initiating cells in an endosteal niche,” Cell Metabolism, vol. 29, no. 4, pp. 950–965.e6, 2019. View at Publisher · View at Google Scholar · View at Scopus